SG44828A1 - New soluble non-cleavable gp160 variant of hybrid form - Google Patents

New soluble non-cleavable gp160 variant of hybrid form

Info

Publication number
SG44828A1
SG44828A1 SG1996008345A SG1996008345A SG44828A1 SG 44828 A1 SG44828 A1 SG 44828A1 SG 1996008345 A SG1996008345 A SG 1996008345A SG 1996008345 A SG1996008345 A SG 1996008345A SG 44828 A1 SG44828 A1 SG 44828A1
Authority
SG
Singapore
Prior art keywords
hiv
region
strain
cleavable
variant
Prior art date
Application number
SG1996008345A
Other languages
English (en)
Inventor
Marie-Paule Kieny
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of SG44828A1 publication Critical patent/SG44828A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Control Of Vehicle Engines Or Engines For Specific Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SG1996008345A 1991-05-02 1992-04-30 New soluble non-cleavable gp160 variant of hybrid form SG44828A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR919105392A FR2676071B1 (fr) 1991-05-02 1991-05-02 Nouveau variant gp160 non-clivable, soluble, de forme hybride.

Publications (1)

Publication Number Publication Date
SG44828A1 true SG44828A1 (en) 1997-12-19

Family

ID=9412448

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996008345A SG44828A1 (en) 1991-05-02 1992-04-30 New soluble non-cleavable gp160 variant of hybrid form

Country Status (12)

Country Link
US (2) US6261799B1 (de)
EP (1) EP0541753B1 (de)
JP (1) JP3453611B2 (de)
AT (1) ATE149203T1 (de)
CA (1) CA2086509C (de)
DE (1) DE69217614T2 (de)
DK (1) DK0541753T3 (de)
ES (1) ES2099257T3 (de)
FR (1) FR2676071B1 (de)
GR (1) GR3023070T3 (de)
SG (1) SG44828A1 (de)
WO (1) WO1992019742A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU677225B2 (en) * 1992-10-06 1997-04-17 Dade Behring Marburg Gmbh Retrovirus from the HIV group and its use
JP3658690B2 (ja) * 1993-01-16 2005-06-08 マンフレート シャヴァラー ウイルスの膜蛋白質の天然ドメインの獲得方法、特にｈｉｖに対するワクチンとしてのそれらの使用
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
NZ520754A (en) 2000-02-10 2004-02-27 Panacos Pharmaceuticals Inc Identifying compounds that disrupt formation of critical gp41 six-helix bundle and conformations necessary for HIV entry thereby blocking virus entry to the cell
WO2009011912A1 (en) * 2007-07-18 2009-01-22 Bristol-Myers Squibb Company A composition for treating hiv comprising virus-like particles
KR102007444B1 (ko) * 2011-04-25 2019-08-06 어드밴스드 바이오사이언스 라보라토리즈, 인코포레이티드 절단형 hiv 피막 단백질(env), 이와 관련된 방법 및 조성물
JP2015522580A (ja) * 2012-07-06 2015-08-06 ノバルティス アーゲー 免疫学的組成物およびその使用
WO2016196471A1 (en) 2015-06-02 2016-12-08 Cooper Human Systems Llc Methods and compositions for treatment of hiv infection
UY37975A (es) * 2017-11-17 2019-02-28 Grifols Diagnostic Solutions Inc Nuevos antigenos de proteinas de la envoltura del virus de la inmunodeficiencia humana (vih) expresados en celulas de mamiferos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2606029B2 (fr) * 1986-04-08 1989-02-03 Transgene Sa Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus
US5169763A (en) * 1986-04-08 1992-12-08 Transgene S.A., Institut Pasteur Viral vector coding glycoprotein of HIV-1
EP0272858A3 (de) * 1986-12-15 1989-07-12 Repligen Corporation Rekombinante HIV-Hüllen-Proteine, hergestellt in Insektenzellen
FR2620030B1 (fr) * 1987-09-07 1990-03-23 Transgene Sa Vecteur d'expression des proteines du virus hiv-2, un agent causal du sida, culture cellulaire infectee ou transformee par ce vecteur, proteines obtenues, vaccin et anticorps obtenus
IL89567A0 (en) * 1988-03-28 1989-09-10 Univ Leland Stanford Junior Mutated hiv envelope protein
CA2003383A1 (en) * 1988-11-23 1990-05-23 Sushil G. Devare Synthetic dna derived recombinant hiv antigens
EP0469089B1 (de) * 1989-04-18 1997-11-19 Applied Biotechnology, Inc. Erzeugung von hybrid-genen und proteinen durch rekombination mittels viren
FR2650954B1 (fr) * 1989-08-18 1992-02-28 Pasteur Institut Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
IE904083A1 (en) * 1989-11-13 1991-05-22 Cambridge Biotech Corp Diagnostic proteins to test for more than one antibody
JP3494300B2 (ja) * 1990-04-03 2004-02-09 ジェネンテック・インコーポレーテッド Ｈｉｖに対する予防接種のための方法および組成物

Also Published As

Publication number Publication date
DK0541753T3 (da) 1997-08-04
FR2676071A1 (fr) 1992-11-06
EP0541753A1 (de) 1993-05-19
CA2086509C (fr) 2003-07-01
GR3023070T3 (en) 1997-07-30
FR2676071B1 (fr) 1994-11-18
CA2086509A1 (fr) 1992-11-03
US6284248B1 (en) 2001-09-04
ES2099257T3 (es) 1997-05-16
EP0541753B1 (de) 1997-02-26
WO1992019742A1 (fr) 1992-11-12
JP3453611B2 (ja) 2003-10-06
US6261799B1 (en) 2001-07-17
ATE149203T1 (de) 1997-03-15
DE69217614T2 (de) 1997-07-10
DE69217614D1 (de) 1997-04-03
JPH05508324A (ja) 1993-11-25

Similar Documents

Publication Publication Date Title
WO2001044286A3 (en) Five-helix protein
IL152507A0 (en) Methods and compositions for impairing multiplication of hiv-1
EP0651818A4 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung.
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
WO1991004273A3 (en) Novel peptides associated with the cd4 binding region of gp120 and their methods of use
EP0330227A3 (de) Lösliche T-4 Derivate
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
SG44828A1 (en) New soluble non-cleavable gp160 variant of hybrid form
CA2131153A1 (en) Peptides stimulating cytotoxic lymphocytes response to hiv-i gp 160
EP0255190A3 (de) Rekombinante Polypeptide und ihre Verwendungen sowie Test für den AIDS-Virus
DE69231705D1 (de) Gag-Env Fusion-Antigen aus HIV
EP0440207A3 (en) Expression of hiv1 and hiv2 polypeptides and use thereof
AU8976691A (en) Selected peptides of the group-specific antigen (gag) of human immunodeficiency virus (hiv), the preparation and use thereof
FR2650954B1 (fr) Composition resultant de la reunion d'un epitope b de la glycoproteine d'enveloppe d'un retrovirus du type iv et d'un epitope t issu d'une proteine distincte codee par ce retrovirus et leur application a la production d'anticorps protecteurs contre le sida
AU651113B2 (en) HIV GP120 monoclonal antibodies
DK1043974T3 (da) Liposomer indeholdende flergrenede peptidkonstruktioner til anvendelse mod human immundefektvirus
AU4832097A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
ES2170161T3 (es) Nuevos conjugados de principios activos y proteinas.
Ivanoff et al. Human immunodeficiency virus antigen.
EP1013766A3 (de) Peptide zum Nachweis von HIV-1-Guppe O
HK167295A (en) Precursors of the HIV-2 retrovirus envelope glycoprotein and related antigens
ES2009280A6 (es) Un metodo para detectar anticuerpos al virus hiv-1 en una muestra.